Mikhail Belevtsev

Belarusian Research Center For Pediatric Oncology and Hematology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Irina Guryanova

Belarusian Research Center For Pediatric Oncology and Hematology

Olga Aleinikova

Belarusian Research Center For Pediatric Oncology and Hematology

Ekaterina Polyakova

Belarusian Research Center For Pediatric Oncology and Hematology

Svetlana O. Sharapova

Belarusian Research Center For Pediatric Oncology and Hematology

АМ

А. М. Попов

National Research Center for Hematology Russian Academy of Medical Sciences

Tatiana Verzhbitskaya

Regional Children's Clinical Hospital No. 1

Grigory Tsaur

Regional Children's Clinical Hospital No. 1

ЛГ

Л. Г. Фечина

Institute of Medical Cell Technologies

Olga Streneva

Regional Children's Clinical Hospital No. 1

Svetlana Aleshkevich

Belarusian Research Center For Pediatric Oncology and Hematology

Cooperative Institutions

Belarusian Research Center For Pediatric Oncology and Hematology

Ministry of Health of the Russian Federation

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

Semmelweis University

Charité - Universitätsmedizin Berlin

National Research Center for Hematology Russian Academy of Medical Sciences

Regional Children's Clinical Hospital No. 1

Goethe University Frankfurt

University of Milan

Pirogov Russian National Research Medical University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The use of next generation sequencing technologies for the diagnosis of inborn errors of immunity

Pediatric Hematology/Oncology and Immunopathology (2023)

Ekaterina Polyakova Irina Guryanova Vladislav Vertelko A. V. Liubushkin Katsiaryna Y. Skapavets

Primary immunodeficiencies are congenital genetically determined immune disorders. Recent advances in molecular genetic technologies have enabled a simultaneous analysis of a large number of genes in a patient. The purpose of this study was to analyze the mutational spectrum in DNA samples collected from patients with various types of primary immunodeficiencies. In this study, we applied next-generation sequencing technology using a panel developed at the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology and consisting of 290 genes that are associated with primary immunodeficiencies according to the existing literature. The testing was carried out in 96 patients with a clinical history suggesting a primary immunological defect. As a result, 37.5% of cases (36/96 patients) were found to harbor genetic defects that lead to disorders of the immune system.

Hematology

Primary Immunodeficiency

10.24287/1726-1708-2023-22-3-177-184

Cite

Citations (0)

Variable CD18 expression in a 22‐year‐old female with leukocyte adhesion deficiency I: Clinical case and literature review

Clinical Case Reports (2023)

Анастасія Бондаренко Oksana Boyarchuk Inga Sakovich Ekaterina Polyakova Alexander A. Migas

Partial leukocyte adhesion deficiency type 1 (LAD-1) deficiency is extremely rare condition with milder infectious manifestation and immune system imbalance leads to increased risks of autoinflammatory complications, such as pyoderma gangrenosum, that can be triggered by trauma or pregnancy. In patients with spice-site ITGB2 variants, partial expression can occur due to different β2 integrin isophorms expression.

Leukocyte adhesion deficiency

Expression (computer science)

10.1002/ccr3.7791

Cite

Citations (4)

Dynamics of TREC and KREC for patients after therapy with anti-CD20 monoclonal antibodies

Clinical Immunology (2023)

Ekaterina Polyakova Maria Stegantseva Tatyana Uglova Mikhail Belevtsev

Immunophenotyping

10.1016/j.clim.2023.109518

Cite

Citations (0)

INTERLEUKIN-2 – AND INTERFERON-ALPHA- INDUCED CHANGES OF PERIPHERAL BLOOD LYMPHOCYTE SUBPOPULATIONS IN CHILDREN WITH ADVANCED MALIGNANCIES, TREATED WITH CHEMOTHERAPY AND WHOLE BODY HYPERTHERMIA

Р. С. Исмаил-заде Mikhail Belevtsev М. П. Потапнев V. P. Savitskiy Э. А. Жаврид

Interferon alfa

Peripheral blood lymphocyte

Alpha (finance)

Source

Cite

Citations (0)

A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL

Cancers (2023)

А. М. Попов Günter Henze Julia Roumiantseva Oleh Bydanov Mikhail Belevtsev

This report presents the results of the assessment of MRD response by multicolor flow cytometry (MFC) with regard to the randomized use of pegylated asparaginase (PEG). In this study, PEG was randomly administered at a dose of 1000 U/m2 on day 3 of induction therapy in children with B-lineage ALL. Methods. Conventional induction therapy consisted of dexamethasone, vincristine, and daunorubicin. MRD data was available in 502 patients who were randomized at the start of induction therapy, standard-risk (SR) patients into three (conventional induction without PEG, induction with additional PEG and with PEG but without daunorubicin) and intermediate-risk (ImR) patients into two groups (with additional PEG and without PEG). Results. The single administration of PEG resulted in a significantly higher proportion of rapid responders, in SR patients even when no anthracyclines were used for induction. In the SR group, the event-free survival of the MFC-MRD fast responders was similar in the PEG− and PEG+ arms (92.0 ± 3.1% vs. 96.2 ± 1.5%, respectively), and the same unfavorable trend was observed for MFC-MRD slow responders (57.5 ± 12.3% vs. 66.7 ± 15.7%, respectively). Results were similar in ImR patients: (94.3 ± 3.2% vs. 95.1 ± 2.4%, for fast responders and 63.3 ± 7.6% vs. 78.1 ± 7.9%, for slow responders in PEG− and PEG+ arms, respectively). However, there is a large difference between the proportion of MFC-MRD slow responders in the PEG− and PEG+ groups (18.3% vs. 5.2% for the SR group and 44.2% vs. 25.0% for the ImR group). Conclusions. Therefore, early use of PEG-ASP not only leads to an accelerated reduction of blasts, but also to an excellent outcome in a significantly larger proportion of patients in both risk groups.

Daunorubicin

Asparaginase

10.3390/cancers15235547

Cite

Citations (2)

Прогностическое значение минимальной остаточной болезни для безрецидивной выживаемости детей с острым лимфобластным лейкозом на протоколе ОЛЛ-МБ-2002 (однофакторный и многофакторный анализ)

Oncohematology (2009)

Савва Наталья Николаевна О. V. Krasko Mikhail Belevtsev В. П. Савицкий Н В Мигаль

220 children with acute lymphoblastic leukemia (ALL) treated according to ALL-MB-2002 protocol are included in the study. Minimal residual disease (MRD) estimated in bone marrow by three-color flow cytometry on day 15 (n=99), day 36 (n=107) and before the maintenance therapy (n=60). Day 36 positive MRD level (≥.01%) as one of unfavorable factors statistically significant worsening of relapse-free survival was revealed (log-rank test; р

Minimal Residual Disease

Log-rank test

Source

Cite

Citations (1)

Peg-Asparaginase Administration on Day 3 of Remission Induction Accelerates MRD Response in Children with B-Cell Precursor Acute Lymphoblastic Leukemia

Blood (2017)

А. М. Попов О. И. Быданов Julia Roumiantseva Svetlana Lagoiko Mikhail Belevtsev

Asparaginase

Acute lymphocytic leukemia

10.1182/blood.v130.suppl_1.3983.3983

Cite

Citations (0)

GENOTYPE-PHENOTYPIC DESCRIPTION OF PATIENTS WITH WISKOTT-ALDRICH SYNDROME

Health and Ecology Issues (2011)

Svetlana O. Sharapova Alexandr Migas Т.А. Углова L. N. Byshniova Mikhail Belevtsev

Six boys aged from 4 months to 15 years old were diagnosed with Wiskott-Aldrich syndrome in the Republican Research Centre for Pediatric Oncology and Hematology. All the patients revealed WAS gene mutations. The missence-mutations in exones 2 and 3, detected in 4 patients prevailed in the spectrum of the mutations. WASP was fully absent in lymphocytes and rather a severe course of the disease was observed in all the patients. Only one child with WAS gene mutation in second exone had a mild course of the disease. The mutations were localized in tenth exone in two patients, which is a nonsense of the mutation. The WASP expression was partially preserved in one patient with such mutation.

Wiskott–Aldrich syndrome

Wiskott–Aldrich syndrome protein

Nonsense mutation

Nonsense

Hematology

10.51523/2708-6011.2011-8-2s-34

Cite

Citations (1)

Inﬂuence of value of minimal residual disease at risk of developing recurrence of relapse in patients with acute lymphoblastic leukemia

Proceedings of the National Academy of Sciences of Belarus Medical series (2019)

E. A. Stolyarova N. V. Migal Mikhail Belevtsev Л. В. Мовчан O. I. Budanov

Minimal residual disease (MRD) is the most significant predictor of the relapse in patients with acute lymphoblastic leukemia (ALL). MRD evaluation is necessary not only for the prediction of the relapse, but for additional stratification of patients by the risk groups in order to address the issue of the therapy individualization and to evaluate the therapy quality. This study analyzes the MRD parameters in patients with ALL at the stage of induction therapy and evaluates the eﬀect of the value of the minimum residual disease on survival rates and the risk of relapse in patients with ALL treated according to protocol ALL-MB 2008.

Minimal Residual Disease

Risk Stratification

10.29235/1814-6023-2019-16-2-202-215

Cite

Citations (0)

Diffuse large B-cell lymphoma in 1-year male with founder Slavic RAG1 mutation: case report

Clinical Immunology (2023)

Tatiana Volodashchik Ekaterina Polyakova Taisiya Mikhalevskaya Inga Sakovich A.Ch. Dubrovskij

10.1016/j.clim.2023.109393

Cite

Citations (0)